<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD03720000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P11473</UniProt_ID>
  <Seq_Length>427</Seq_Length>
  <Molecule_Weight>48289</Molecule_Weight>
  <KEGG_ID>hsa:7421</KEGG_ID>
  <Orthology_ID>K08539</Orthology_ID>
  <EBI_ID>EBI-286357</EBI_ID>
  <Function_Summary>Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Regulates transcription of hormone sensitive genes via its association with the WINAC complex, a chromatin-remodeling complex. Recruited to promoters via its interaction with the WINAC complex subunit BAZ1B/WSTF, which mediates the interaction with acetylated histones, an essential step for VDR-promoter association. Plays a central role in calcium homeostasis.</Function_Summary>
  <Pfam_ID>PF00104:Hormone_recep@@PF00105:zf-C4</Pfam_ID>
  <Allosteric_Activator_Count>10</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>4</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>VDR</Alias>
      <Alias>Nuclear receptor subfamily 1 group I member 1</Alias>
      <Alias>1,25-dihydroxyvitamin D3 receptor</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Combining with vitamin D3, cholecalciferol, to initiate a change in cell activity.</Detail>
      <Keyword>Vitamin D3 receptor activity</Keyword>
      <Ontology_ID>GO:0008434</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with DNA of a specific nucleotide composition, e.g. GC-rich DNA binding, or with a specific sequence motif or type of DNA e.g. promotor binding or rDNA binding.</Detail>
      <Keyword>Sequence-specific DNA binding</Keyword>
      <Ontology_ID>GO:0043565</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with a steroid hormone to initiate a change in cell activity.</Detail>
      <Keyword>Steroid hormone receptor activity</Keyword>
      <Ontology_ID>GO:0003707</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with zinc (Zn) ions.</Detail>
      <Keyword>Zinc ion binding</Keyword>
      <Ontology_ID>GO:0008270</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Any molecular function by which a gene product interacts selectively with DNA (deoxyribonucleic acid).</Detail>
      <Keyword>DNA binding</Keyword>
      <Ontology_ID>GO:0003677</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a retinoid X receptor.</Detail>
      <Keyword>Retinoid X receptor binding</Keyword>
      <Ontology_ID>GO:0046965</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>362</Position>
      <Original>Thr</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>47</Position>
      <Original>Phe</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>80</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>73</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>391</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>33</Position>
      <Original>Gly</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>230</Position>
      <Original>Leu</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>50</Position>
      <Original>Arg</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>45</Position>
      <Original>Lys</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>35</Position>
      <Original>His</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>305</Position>
      <Original>His</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>274</Position>
      <Original>Arg</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>314</Position>
      <Original>Ile</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>46</Position>
      <Original>Gly</Original>
      <Variation>Asp</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process in which a ligand-bound hormone receptor acts in the nucleus to modulate the frequency, rate or extent of transcription from an RNA polymerase II promoter.</Detail>
      <Keyword>Regulation of transcription from RNA polymerase II promoter by nuclear hormone receptor</Keyword>
      <Ontology_ID>GO:0034339</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the rate, frequency or extent of calcidiol 1-monooxygenase activity. Calcidiol 1-monooxygenase activity is catalysis of the reaction: calcidiol + NADPH + H+ + O2 = calcitriol + NADP+ + H2O.</Detail>
      <Keyword>Regulation of calcidiol 1-monooxygenase activity</Keyword>
      <Ontology_ID>GO:0060558</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Regulation of transcription</Keyword>
      <Ontology_ID>GO:0045449</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the rate, frequency or extent of vitamin D 24-hydroxylase activity. Vitamin D 24-hydroxylase activity catalyzes the hydroxylation of C-24 of any form of vitamin D.</Detail>
      <Keyword>Positive regulation of vitamin D 24-hydroxylase activity</Keyword>
      <Ontology_ID>GO:0010980</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular and vascular changes occurring in the endometrium of the pregnant uterus just after the onset of blastocyst implantation. This process involves the proliferation and differentiation of the fibroblast-like endometrial stromal cells into large, polyploid decidual cells that eventually form the maternal component of the placenta.</Detail>
      <Keyword>Decidualization</Keyword>
      <Ontology_ID>GO:0046697</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of transcription from the RNA polymerase II promoter.</Detail>
      <Keyword>Positive regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0045944</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of transcription from an RNA polymerase II promoter.</Detail>
      <Keyword>Negative regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0000122</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of keratinocyte differentiation.</Detail>
      <Keyword>Positive regulation of keratinocyte differentiation</Keyword>
      <Ontology_ID>GO:0045618</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency or extent of keratinocyte proliferation. Keratinocyte proliferation is the multiplication or reproduction of keratinocytes, resulting in the expansion of a cell population.</Detail>
      <Keyword>Negative regulation of keratinocyte proliferation</Keyword>
      <Ontology_ID>GO:0010839</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The developmental process in which the size or shape of a cell is generated and organized.</Detail>
      <Keyword>Cell morphogenesis</Keyword>
      <Ontology_ID>GO:0000902</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Transcription</Keyword>
      <Ontology_ID>GO:0006350</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <Molecule_Seq>
    <Protein_Seq>MEAMAASTSLPDPGDFDRNVPRICGVCGDRATGFHFNAMTCEGCKGFFRRSMKRKALFTCPFNGDCRITKDNRRHCQACRLKRCVDIGMMKEFILTDEEVQRKREMILKRKEEEALKDSLRPKLSEEQQRIIAILLDAHHKTYDPTYSDFCQFRPPVRVNDGGGSHPSRPNSRHTPSFSGDSSSSCSDHCITSSDMMDSSSFSNLDLSEEDSDDPSVTLELSQLSMLPHLADLVSYSIQKVIGFAKMIPGFRDLTSEDQIVLLKSSAIEVIMLRSNESFTMDDMSWTCGNQDYKYRVSDVTKAGHSLELIEPLIKFQVGLKKLNLHEEEHVLLMAICIVSPDRPGVQDAALIEAIQDRLSNTLQTYIRCRHPPPGSHLLYAKMIQKLADLRSLNEEHSKQYRCLSFQPECSMKLTPLVLEVFGNEIS</Protein_Seq>
    <DNA_Seq>ACAGAAGAGCACCCCTGGGCTCCACTTACCTGCCCCCTGCTCCTTCAGGGATGGAGGCAATGGCGGCCAGCACTTCCCTGCCTGACCCTGGAGACTTTGACCGGAACGTGCCCCGGATCTGTGGGGTGTGTGGAGACCGAGCCACTGGCTTTCACTTCAATGCTATGACCTGTGAAGGCTGCAAAGGCTTCTTCAGGCGAAGCATGAAGCGGAAGGCACTATTCACCTGCCCCTTCAACGGGGACTGCCGCATCACCAAGGACAACCGACGCCACTGCCAGGCCTGCCGGCTCAAACGCTGTGTGGACATCGGCATGATGAAGGAGTTCATTCTGACAGATGAGGAAGTGCAGAGGAAGCGGGAGATGATCCTGAAGCGGAAGGAGGAGGAGGCCTTGAAGGACAGTCTGCGGCCCAAGCTGTCTGAGGAGCAGCAGCGCATCATTGCCATACTGCTGGACGCCCACCATAAGACCTACGACCCCACCTACTCCGACTTCTGCCAGTTCCGGCCTCCAGTTCGTGTGAATGATGGTGGAGGGAGCCATCCTTCCAGGCCCAACTCCAGACACACTCCCAGCTTCTCTGGGGACTCCTCCTCCTCCTGCTCAGATCACTGTATCACCTCTTCAGACATGATGGACTCGTCCAGCTTCTCCAATCTGGATCTGAGTGAAGAAGATTCAGATGACCCTTCTGTGACCCTAGAGCTGTCCCAGCTCTCCATGCTGCCCCACCTGGCTGACCTGGTCAGTTACAGCATCCAAAAGGTCATTGGCTTTGCTAAGATGATACCAGGATTCAGAGACCTCACCTCTGAGGACCAGATCGTACTGCTGAAGTCAAGTGCCATTGAGGTCATCATGTTGCGCTCCAATGAGTCCTTCACCATGGACGACATGTCCTGGACCTGTGGCAACCAAGACTACAAGTACCGCGTCAGTGACGTGACCAAAGCCGGACACAGCCTGGAGCTGATTGAGCCCCTCATCAAGTTCCAGGTGGGACTGAAGAAGCTGAACTTGCATGAGGAGGAGCATGTCCTGCTCATGGCCATCTGCATCGTCTCCCCAGATCGTCCTGGGGTGCAGGACGCCGCGCTGATCGAGGCCATCCAGGACCGCCTGTCCAACACACTGCAGACGTACATCCGCTGCCGCCACCCGCCCCCGGGCAGCCACCTGCTCTATGCCAAGATGATCCAGAAGCTAGCCGACCTGCGCAGCCTCAATGAGGAGCACTCCAAGCAGTACCGCTGCCTCTCCTTCCAGCCTGAGTGCAGCATGAAGCTAACGCCCCTTGTGCTCGAAGTGTTTGGCAATGAGATCTCCTGAC</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Bone</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Kidney</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Intestine</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>VDR</Gene_Name>
    <Gene_Alias>NR1I1</Gene_Alias>
    <Gene_ID>7421</Gene_ID>
    <Genbank_ACCN>NM_000376</Genbank_ACCN>
    <Protein_ACCN>NP_000367</Protein_ACCN>
    <HGNC_ID>12679</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/7421</Gene_URL>
    <UCSC_ID>uc001rql.3</UCSC_ID>
    <EMBL_ID>ENSG00000111424</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P04637</Uniprot_ID>
      <Gene_Name>TP53</Gene_Name>
      <EBI_ID>EBI-366083</EBI_ID>
      <PPI_EBI_URL>EBI-286357,EBI-366083</PPI_EBI_URL>
      <Experiment_Number>6</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9JLI4</Uniprot_ID>
      <Gene_Name>Ncoa6</Gene_Name>
      <EBI_ID>EBI-286271</EBI_ID>
      <PPI_EBI_URL>EBI-286357,EBI-286271</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P26045</Uniprot_ID>
      <Gene_Name>PTPN3</Gene_Name>
      <EBI_ID>EBI-1047946</EBI_ID>
      <PPI_EBI_URL>EBI-286357,EBI-1047946</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Extrapulmonary Tuberculosis</Disease_Name>
      <Disease_Detail>Extrapulmonary Tuberculosis</Disease_Detail>
      <Disease_DB>EXT033</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/extrapulmonary_tuberculosis?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Dentinogenesis Imperfecta</Disease_Name>
      <Disease_Detail>Dentinogenesis Imperfecta</Disease_Detail>
      <Disease_DB>DNT011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/dentinogenesis_imperfecta?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lead Poisoning</Disease_Name>
      <Disease_Detail>Lead Poisoning</Disease_Detail>
      <Disease_DB>LDP002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lead_poisoning?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Osteoporosis, Involutional</Disease_Name>
      <Disease_Detail>Osteoporosis</Disease_Detail>
      <Disease_DB>OST082</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/osteoporosis_involutional?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hyperparathyroidism</Disease_Name>
      <Disease_Detail>Hyperparathyroidism</Disease_Detail>
      <Disease_DB>HYP069</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hyperparathyroidism?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Spinal Stenosis</Disease_Name>
      <Disease_Detail>Spinal Stenosis</Disease_Detail>
      <Disease_DB>SPN027</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/spinal_stenosis?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Campylobacteriosis</Disease_Name>
      <Disease_Detail>Campylobacteriosis</Disease_Detail>
      <Disease_DB>CMP002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/campylobacteriosis?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Caveolinopathies</Disease_Name>
      <Disease_Detail>Caveolinopathies</Disease_Detail>
      <Disease_DB>CVL001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/caveolinopathies?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Multidrug-Resistant Tuberculosis</Disease_Name>
      <Disease_Detail>Multidrug-Resistant Tuberculosis</Disease_Detail>
      <Disease_DB>MLT006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/multidrug_resistant_tuberculosis?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Colorectal Cancer</Disease_Name>
      <Disease_Detail>Colorectal Cancer</Disease_Detail>
      <Disease_DB>CLR023</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/colorectal_cancer?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Osteoporosis</Disease_Name>
      <Disease_Detail>Osteoporosis</Disease_Detail>
      <Disease_DB>OST002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/osteoporosis?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Breast Cancer</Disease_Name>
      <Disease_Detail>Breast Cancer</Disease_Detail>
      <Disease_DB>BRS047</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/breast_cancer?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Rickets</Disease_Name>
      <Disease_Detail>Rickets</Disease_Detail>
      <Disease_DB>RCK004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/rickets?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Spondylosis</Disease_Name>
      <Disease_Detail>Spondylosis</Disease_Detail>
      <Disease_DB>SPN020</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/spondylosis?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lumbar Disc Disease</Disease_Name>
      <Disease_Detail>Lumbar Disc Disease</Disease_Detail>
      <Disease_DB>LMB051</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lumbar_disc_disease?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Vitamin D-Dependent Rickets Type Ii</Disease_Name>
      <Disease_Detail>Vitamin D-Dependent Rickets Type Ii</Disease_Detail>
      <Disease_DB>VTM007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/vitamin_d_dependent_rickets_type_ii?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Tuberculosis</Disease_Name>
      <Disease_Detail>Tuberculosis</Disease_Detail>
      <Disease_DB>TBR010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/tuberculosis?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Intervertebral Disc Disease</Disease_Name>
      <Disease_Detail>Intervertebral Disc Disease</Disease_Detail>
      <Disease_DB>INT146</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/intervertebral_disc_disease?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Rickets, Vitamin D-Resistant, Type Iia</Disease_Name>
      <Disease_Detail>Rickets</Disease_Detail>
      <Disease_DB>RCK007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/rickets_vitamin_d_resistant_type_iia?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Atrichia with Papular Lesions</Disease_Name>
      <Disease_Detail>Atrichia with Papular Lesions</Disease_Detail>
      <Disease_DB>ATR013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/atrichia_with_papular_lesions?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypercalciuria, Absorptive</Disease_Name>
      <Disease_Detail>Hypercalciuria, Absorptive</Disease_Detail>
      <Disease_DB>HYP268</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypercalciuria_absorptive?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Syringomyelia</Disease_Name>
      <Disease_Detail>Syringomyelia</Disease_Detail>
      <Disease_DB>SYR001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/syringomyelia?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Prostate Cancer</Disease_Name>
      <Disease_Detail>Prostate Cancer</Disease_Detail>
      <Disease_DB>PRS040</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/prostate_cancer?search=VDR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Degenerative Disc Disease</Disease_Name>
      <Disease_Detail>Degenerative Disc Disease</Disease_Detail>
      <Disease_DB>DGN001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/degenerative_disc_disease?search=VDR#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Crystal structure of the VDR LBD complexed to seocalcitol.</PDB_Title>
      <PDB_ID>1S0Z</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1S0Z</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>SEOCALCITOL</Ligand_Name>
      <PubMed_Title>Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification.</PubMed_Title>
      <Author>Tocchini-Valentini G, et al.</Author>
      <Journal>J Med Chem.2004 Apr 8;47(8):1956-61.</Journal>
      <PubMed_ID>15055995</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of VDR LBD in complex with 2alpha-(1-propoxy) calcitriol</PDB_Title>
      <PDB_ID>2HAS</PDB_ID>
      <Resolution>1.96</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2HAS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2ALPHA-PROPOXY-1ALPHA,25-DIHYDROXYVITAMIN D3</Ligand_Name>
      <PubMed_Title>Probing a Water Channel near the A-Ring of Receptor-Bound 1alpha,25-Dihydroxyvitamin D3 with Selected 2alpha-Substituted Analogues</PubMed_Title>
      <Author>Hourai S, et al.</Author>
      <Journal>J Med Chem.2006 Aug 24;49(17):5199-205.</Journal>
      <PubMed_ID>16913708</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of VDR DNA-binding Domain Bound to Mouse Osteopontin (SPP) Response Element</PDB_Title>
      <PDB_ID>1KB2</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1KB2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis of VDR-DNA interactions on direct repeat response elements.</PubMed_Title>
      <Author>Shaffer PL, et al.</Author>
      <Journal>EMBO J.2002 May 1;21(9):2242-52.</Journal>
      <PubMed_ID>11980721</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of VDR ligand binding domain complexed to calcipotriol.</PDB_Title>
      <PDB_ID>1S19</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1S19</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>CALCIPOTRIOL</Ligand_Name>
      <PubMed_Title>Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification.</PubMed_Title>
      <Author>Tocchini-Valentini G, et al.</Author>
      <Journal>J Med Chem.2004 Apr 8;47(8):1956-61.</Journal>
      <PubMed_ID>15055995</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the vdr ligand binding domain complexed to TX522</PDB_Title>
      <PDB_ID>1TXI</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TXI</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>(1R,3R)-5-((Z)-2-((1R,7AS)-HEXAHYDRO-1-((S)- 6-HYDROXY-6-METHYLHEPT-4-YN-2-YL)
-7A-METHYL- 1H-INDEN-4(7AH)-YLIDENE)ETHYLIDENE)CYCLOHEXANE- 1,3-DIOL</Ligand_Name>
      <PubMed_Title>Superagonistic Action of 14-epi-Analogs of 1,25-Dihydroxyvitamin D Explained by Vitamin D Receptor-Coactivator Interaction</PubMed_Title>
      <Author>Eelen G, et al.</Author>
      <Journal>Mol Pharmacol.2005 May;67(5):1566-73. Epub  2005 Feb 22.</Journal>
      <PubMed_ID>15728261</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of VDR LBD in complex with 2 alpha-(3-hydroxy-1-propoxy) calcitriol</PDB_Title>
      <PDB_ID>2HAR</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2HAR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2ALPHA-(3-HYDROXYPROPOXY)-1ALPHA,25-DIHYDROXYVITAMIN D3</Ligand_Name>
      <PubMed_Title>Probing a Water Channel near the A-Ring of Receptor-Bound 1alpha,25-Dihydroxyvitamin D3 with Selected 2alpha-Substituted Analogues</PubMed_Title>
      <Author>Hourai S, et al.</Author>
      <Journal>J Med Chem.2006 Aug 24;49(17):5199-205.</Journal>
      <PubMed_ID>16913708</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of VDR DNA-binding Domain Bound to a Canonical Direct Repeat with Three Base Pair Spacer (DR3) Response Element</PDB_Title>
      <PDB_ID>1KB4</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1KB4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis of VDR-DNA interactions on direct repeat response elements.</PubMed_Title>
      <Author>Shaffer PL, et al.</Author>
      <Journal>EMBO J.2002 May 1;21(9):2242-52.</Journal>
      <PubMed_ID>11980721</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure Of The Nuclear Receptor For Vitamin D Ligand Binding Domain Bound to MC1288</PDB_Title>
      <PDB_ID>1IE9</PDB_ID>
      <Resolution>1.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IE9</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03720001</ASD_Ligand>
      <Ligand_Name>5-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A- METHYL-OCTAHYDRO-INDEN-4-YLIDENE]
-ETHYLIDENE}- 4-METHYLENE-CYCLOHEXANE-1,3-DIOL</Ligand_Name>
      <PubMed_Title>Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands.</PubMed_Title>
      <Author>Tocchini-Valentini G, et al.</Author>
      <Journal>Proc Natl Acad Sci U S A.2001 May 8;98(10):5491-6.</Journal>
      <PubMed_ID>11344298</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the human VDR ligand binding domain bound to the synthetic agonist compound 2alpha-methyl-AMCR277A(C23S)</PDB_Title>
      <PDB_ID>3A3Z</PDB_ID>
      <Resolution>1.72</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3A3Z</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>(1S,2S,3R,5Z,7E,14beta,17alpha)-17-[(2S,4S)- 4-(2-hydroxy-2-methylpropyl)-2
-methyltetrahydrofuran- 2-yl]-2-methyl-9,10-secoandrosta-5,7,10-triene- 1,3-diol$SULFATE ION</Ligand_Name>
      <PubMed_Title>Structure-Function Relationships and Crystal Structures of the Vitamin D Receptor Bound 2alpha-Methyl-(20S,23S)- and 2alpha-Methyl-(20S,23R)-epoxymethano-1alpha,25-dihydroxyvitamin D(3)</PubMed_Title>
      <Author>Antony P, et al.</Author>
      <Journal>J Med Chem.2010 Feb 11;53(3):1159-71.</Journal>
      <PubMed_ID>20070104</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of VDR DNA-binding Domain Bound to Rat Osteocalcin (OC) Response Element</PDB_Title>
      <PDB_ID>1KB6</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1KB6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis of VDR-DNA interactions on direct repeat response elements.</PubMed_Title>
      <Author>Shaffer PL, et al.</Author>
      <Journal>EMBO J.2002 May 1;21(9):2242-52.</Journal>
      <PubMed_ID>11980721</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of family II Inorganic pyrophosphatase in complex with PNP</PDB_Title>
      <PDB_ID>2HAW</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2HAW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>PENTAETHYLENE GLYCOL$IMIDODIPHOSPHORIC ACID$CHLORIDE ION$FLUORIDE ION$GLYCEROL$MAGNESIUM ION$TETRAETHYLENE GLYCOL$SULFATE ION</Ligand_Name>
      <PubMed_Title>A trimetal site and substrate distortion in a family II inorganic pyrophosphatase</PubMed_Title>
      <Author>Fabrichniy IP, et al.</Author>
      <Journal>J Biol Chem.2007 Jan 12;282(2):1422-31. Epub  2006 Nov 8.</Journal>
      <PubMed_ID>17095506</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Vitmain D Receptor and 9-cis Retinoic Acid Receptor DNA-Binding Domains Bound to a DR3 Response Element</PDB_Title>
      <PDB_ID>1YNW</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1YNW</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural analysis of RXR-VDR interactions on DR3 DNA</PubMed_Title>
      <Author>Shaffer PL, et al.</Author>
      <Journal>J Steroid Biochem Mol Biol.2004 May;89-90(1-5):215-9.</Journal>
      <PubMed_ID>15225774</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure Of The Nuclear Receptor For Vitamin D Ligand Binding Domain Bound to KH1060</PDB_Title>
      <PDB_ID>1IE8</PDB_ID>
      <Resolution>1.52</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IE8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>5-(2-{1-[1-(4-ETHYL-4-HYDROXY-HEXYLOXY)-ETHYL]- 7A-METHYL-OCTAHYDRO-INDEN-4
-YLIDENE}-ETHYLIDENE)- 4-METHYLENE-CYCLOHEXANE-1,3-DIOL</Ligand_Name>
      <PubMed_Title>Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands.</PubMed_Title>
      <Author>Tocchini-Valentini G, et al.</Author>
      <Journal>Proc Natl Acad Sci U S A.2001 May 8;98(10):5491-6.</Journal>
      <PubMed_ID>11344298</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the human VDR ligand binding domain bound to the synthetic agonist compound 2alpha-methyl-AMCR277B(C23R)</PDB_Title>
      <PDB_ID>3A40</PDB_ID>
      <Resolution>1.45</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3A40</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>(1S,2S,3R,5Z,7E,14beta,17alpha,23R)-23-(2- hydroxy-2-methylpropyl)-2-methyl
-20,24-epoxy- 9,10-secochola-5,7,10-triene-1,3-diol$SULFATE ION</Ligand_Name>
      <PubMed_Title>Structure-Function Relationships and Crystal Structures of the Vitamin D Receptor Bound 2alpha-Methyl-(20S,23S)- and 2alpha-Methyl-(20S,23R)-epoxymethano-1alpha,25-dihydroxyvitamin D(3)</PubMed_Title>
      <Author>Antony P, et al.</Author>
      <Journal>J Med Chem.2010 Feb 11;53(3):1159-71.</Journal>
      <PubMed_ID>20070104</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of VDR LBD in complex with 2alpha(3-hydroxy-1-propyl) calcitriol</PDB_Title>
      <PDB_ID>2HB7</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2HB7</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2ALPHA-(3-HYDROXYPROPYL)-1ALPHA,25-DIHYDROXYVITAMIN D3</Ligand_Name>
      <PubMed_Title>Probing a Water Channel near the A-Ring of Receptor-Bound 1alpha,25-Dihydroxyvitamin D3 with Selected 2alpha-Substituted Analogues</PubMed_Title>
      <Author>Hourai S, et al.</Author>
      <Journal>J Med Chem.2006 Aug 24;49(17):5199-205.</Journal>
      <PubMed_ID>16913708</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of VDR LBD in complex with 2alpha-methyl calcitriol</PDB_Title>
      <PDB_ID>2HB8</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2HB8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <Ligand_Name>2ALPHA-METHYL-1ALPHA,25-DIHYDROXY-VITAMIN D3</Ligand_Name>
      <PubMed_Title>Probing a Water Channel near the A-Ring of Receptor-Bound 1alpha,25-Dihydroxyvitamin D3 with Selected 2alpha-Substituted Analogues</PubMed_Title>
      <Author>Hourai S, et al.</Author>
      <Journal>J Med Chem.2006 Aug 24;49(17):5199-205.</Journal>
      <PubMed_ID>16913708</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE NUCLEAR RECEPTOR FOR VITAMIN D COMPLEXED TO VITAMIN D</PDB_Title>
      <PDB_ID>1DB1</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DB1</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03720001</ASD_Ligand>
      <Ligand_Name>5-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A- METHYL-OCTAHYDRO-INDEN-4-YLIDENE]
-ETHYLIDENE}- 4-METHYLENE-CYCLOHEXANE-1,3-DIOL</Ligand_Name>
      <PubMed_Title>The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand.</PubMed_Title>
      <Author>Rochel N, et al.</Author>
      <Journal>Mol Cell.2000 Jan;5(1):173-9.</Journal>
      <PubMed_ID>10678179</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04978</Pathway_ID>
      <Pathway_Title>Mineral absorption</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Digestive system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04961</Pathway_ID>
      <Pathway_Title>Endocrine and other factor-regulated calcium reabsorption</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Excretory system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05152</Pathway_ID>
      <Pathway_Title>Tuberculosis</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All alpha proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.b.cdh.b.b.ca.html</SCOP_URL>
    <CATH_Class>Mainly alpha</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1db1</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Detail>site,276,Asn;site,278,Ser;site,143,Tyr;site,274,Arg;site,237,Ser;site,397,His;site,305,His</Site_Detail>
      <Site_Reference>Yamamoto K, et al. J Med Chem. 2006,49(4):1313-1324.</Site_Reference>
      <Site_Type>Oligomerization</Site_Type>
      <PDB_ID>1DB1;1IE9</PDB_ID>
      <PubMed_ID>16480267</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Allosteric_Pathway>
    <Method>Statistical coupling analysis, alanine scanning mutational analysis (ASMA). </Method>
    <Verified__Residue>Y143, Y147, F150, I238, I271, R274, W286, Y295, H397, Y401, V418, F422</Verified__Residue>
    <PubMed_Title>Yamamoto K, et al. J Med Chem. 2006,49(4):1313-1324.@@Shulman AI, et al. Cell. 2004,116(3):417-429.</PubMed_Title>
    <PubMed_ID>16480267@@15016376</PubMed_ID>
    <is__ref__img>Yes</is__ref__img>
    <is__display>No</is__display>
    <in__pathway__browse>Yes</in__pathway__browse>
  </Allosteric_Pathway>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD03720001</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720002</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720003</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720004</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720005</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720006</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720007</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720008</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720009</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720010</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720011</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720012</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720013</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03720014</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>